Stock Analiz

Soligenix, Inc. SNGX

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$0.32Market cap $8M
Open the interactive analysis →

Soligenix, Inc. (SNGX) is a healthcare company listed in the US with a market value of about $8M.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -171%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.

About Soligenix

Soligenix is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $7M in 2014 to $119371 in 2024, a decline of about 33.5% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 2791% over three years (dilution for shareholders).

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B1.2
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-136.9%
Shareholder yield0.0%
Intrinsic value vs. price−100%

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-2658.4%
ROIC (5-yr avg.)-171.2%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue—$119371$839359$948911$824268$2M$5M$5M$5M$10M
Net income-$11M-$8M-$6M-$14M-$13M-$18M-$9M-$9M-$7M-$3M
Free cash flow-$10M—————————
EPS (diluted)$-2.14$-4.98$-12.66$-76.94$-75.02$-153.56$-115.17$-163.16$-278.33$-321.52
Net margin—-6925.1%-731.6%-1454.1%-1522.7%-749.7%-202.1%-169.8%-131.6%-31.1%
ROIC-200.5%-212.6%-158.7%—-113.2%-124.2%-630.0%-109.8%-43.4%-27.7%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Soligenix stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Soligenix pay a dividend?

Not currently.

Is Soligenix a good stock to buy?

We do not give buy or sell advice. Soligenix scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.